Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eal
- Development stage
- Unknown
- Lead developer
- Immunotech Biopharm
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
EAL (Effective Activated Lymphocyte) is an autologous cellular immunotherapy developed by Beijing Yongtai Biologics (also known as Beijing Weixiao Biotechnology Development). The therapy consists of activated T lymphocytes, primarily CD8+ T cells, which are expanded ex vivo from a patient's peripheral blood mononuclear cells (PBMCs) and subsequently re-infused. EAL is designed to recognize multiple tumor-associated antigens and mediate broad antitumor activity to prevent the recurrence of solid tumors, particularly hepatocellular carcinoma (HCC) following surgical resection. It is currently in late-stage clinical development in China and represents a multi-target approach to immunotherapy intended to overcome tumor heterogeneity.
- Brand names
- EAL
- Other names
- Effective Activated Lymphocyteautologous activated T lymphocytesactivated T lymphocytes
02
Targets
NeoAg-MHC (Patient-specific tumor neoantigen-major histocompatibility complex)
Beyond the preview
Go deeper on eal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eal.